AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.
Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, Kim H, Li M, Downey TJ, Dyer MD, Sun Y, Sun J, Beasley EM, Chung HC, Noh SH, Weinstein JN, Liu CG, Powis G
Cancer Res. 2012 May 15;72(10):2512-21
Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.
Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT
Mol Cancer Res. 2012 Mar;10(3):392-400
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G
J Natl Cancer Inst. 2012 Feb 8;104(3):228-39
Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010.
Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ, NCI Workshop Participants
Radiat Res. 2011 Sep;176(3):e0016-21
The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.
Koh MY, Lemos R, Liu X, Powis G
Cancer Res. 2011 Jun 1;71(11):4015-27
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK
Neuro Oncol. 2011 Apr;13(4):367-75
HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance.
Schwartz DL, Bankson J, Bidaut L, He Y, Williams R, Lemos R, Thitai AK, Oh J, Volgin A, Soghomonyan S, Yeh HH, Nishii R, Mukhopadhay U, Alauddin M, Mushkudiani I, Kuno N, Krishnan S, Bornman W, Lai SY, Powis G, Hazle J, Gelovani J
Mol Cancer Res. 2011 Mar;9(3):259-70
Development of sulfonamide AKT PH domain inhibitors.
Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA
Bioorg Med Chem. 2011 Mar 15;19(6):2046-54
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.
Kim YH, Coon A, Baker AF, Powis G
Cancer Chemother Pharmacol. 2011 Aug;68(2):405-13
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O
Int J Cancer. 2011 Feb 15;128(4):787-96
View All Publications
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JJ, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L
J Clin Oncol. 2015 Oct 12;
Garth Powis's Research Focus
Solid tumors exist in a stressed environment for cell growth. In order to survive, cancer cells initiate specific adaptive and constitutive changes allowing them to adapt to the hostile hypoxic environment, escape cell death and increase formation of new blood vessels and metastasis. All of these responses lead to highly aggressive tumors that are resistant to therapy. In order to identify novel targets for therapeutic intervention that is applicable to a wide variety of tumor types, our lab studies the mechanisms that enable cancer cells to survive stress.
About Garth Powis
Powis is a native of the U.K., where he trained at Oxford University. He worked at the Mayo Clinic, becoming deputy chair of Pharmacology; at University of Arizona Cancer Center as director of Basic Research; and most recently at MD Anderson Cancer Center, where he served as chair of Experimental Therapeutics and director of the Center for Targeted Therapy.
Powis is a molecular and translational pharmacologist with more than 350 publications and 15 patents. His research focuses on the mechanisms that enable cancer cells to survive stress. Powis’ work has resulted in three novel cancer drugs currently in clinical trials. The expertise he brings to Sanford-Burnham encompasses all stages of cancer drug discovery and development, from early target identification to clinical studies with cancer patients.
1970 Merton College, Oxford, United Kingdom, D. Phil., Biochemistry and Pharmacology
1967 Birmingham University, England, United Kingdom, B.Sc., Hons. (1st Class), Biochemistry and Pharmacology